Loncastuximab Tesirine for Non-Hodgkin's Lymphoma

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Non-Hodgkin's Lymphoma+1 MoreLoncastuximab Tesirine - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test if a new drug, loncastuximab tesirine, can help control large B-cell lymphoma that has returned or is resistant to CAR T-cell therapy. The safety and possible effects of the new drug will also be studied.

Eligible Conditions
  • Non-Hodgkin's Lymphoma
  • Lymphoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: through study completion and or average of 1 year

Year 1
Rate of conversion to complete response

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

Loncastuximab Tesirine
1 of 1

Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: Loncastuximab Tesirine · No Placebo Group · Phase 2

Loncastuximab Tesirine
Drug
Experimental Group · 1 Intervention: Loncastuximab Tesirine · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Loncastuximab Tesirine
2021
Completed Phase 2
~10

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion and or average of 1 year

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,802 Previous Clinical Trials
1,788,873 Total Patients Enrolled
Paolo Strati, MDPrincipal InvestigatorM.D. Anderson Cancer Center
1 Previous Clinical Trials
52 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have no evidence of disease or have disease that is in a stable or progressive state.
You have achieved a complete response according to the 2014 response criteria.
You must have received CAR T-cell therapy at least 30 days before the date of the assessment.
CD19 expression is not required for enrolment in this trial.
You have a neutrophil count of ≥ 1.
Platelet count of ≥ 50×109/L without transfusion for 7 days prior to screening assessment.